September started off pretty weak but this has always been a difficult month for the markets. I do not really see this as a change in the market and more as a consolidation. Of course, there is only so much the market can decline before it becomes something more but at this point, I would […]
August 28th Biotech Update
Moving is a pain, but unpacking is agony. LOL. The market and sector, however, look a lot better than my house. While there has been a little pullback, I really see it more as the pullback that refreshes the move higher as opposed to a sign that something is wrong in the sector. Obviously, it […]
August 22nd Biotech Update
I suspected that we would have paused this week but the sector has had a nice continuation this week despite hitting what I thought would have been natural resistance. That is a nice sign of strength but I still think the sector is a little extended in the immediate term and likely needs a to […]
August 20th Biotech Update
Well, I did not think my return would be celebrated so much by the sector. All kidding aside, it was quite a nice day yesterday and I am a little surprised that we did not have more resistance at the $98 levels. We did spend a couple of days bouncing against those levels but I […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
